ST. GALL, Switzerland–(BUSINESS WIRE)–Regulatory news:
CSL Limited (ASX: CSL; USOTC: CSLLY) yesterday announced an update regarding the acquisition of Vifor Pharma AG. CSL has previously indicated that it expects to be able to complete the acquisition of Vifor Pharma AG by June 2022. Although certain antitrust authorities have approved the transaction, some approvals are still pending.
Delays in the regulatory approval process are not unusual. CSL and Vifor Pharma continue to work closely with the respective remaining competition authorities in their review of the tender offer. CSL and Vifor Pharma plan to provide an update to shareholders and investors as soon as the timeline becomes clearer.
An exact closing and settlement date will be communicated once all regulatory approvals have been received. CSL remains confident to complete its acquisition of Vifor Pharma AG.
About the Vifor Pharma Group
The Vifor Pharma Group is a global pharmaceutical company. It aims to become the world leader in iron deficiency and nephrology. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions in iron, dialysis, nephrology and rare diseases. The Vifor Pharma Group strives to help patients around the world with serious, chronic and rare diseases lead better and healthier lives. She specializes in strategic global partnerships, licensing and development, manufacturing and marketing of pharmaceutical products for precision patient care. The Vifor Pharma Group has a leading position in all its core businesses and comprises the companies: Vifor Pharma, Sanifit Therapeutics and Vifor Fresenius Medical Care Renal Pharma (a joint venture with Fresenius Medical Care). The Vifor Pharma Group is headquartered in Switzerland and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348). For more information, please visit viverpharma.com